Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic
strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine …

Targeting angiogenesis has remained one of the important aspects in disease biology in
general and cancer in particular. Currently (June 2023), over 593 clinical trials have been …

Background Pre-clinical and clinical evidences support that simultaneous blockade of
programmed death-1 (PD-1) and vascular endothelial growth factor receptor (VEGFR) can …

Favorable clinical evidence suggests that the next trend in new treatments for advanced non-
small cell lung cancer (NSCLC) will be combination therapies. However, inevitable …

Oral cavity squamous cell carcinoma (OCSCC) represents a serious health and socio-
economic problem in different geographical areas of the world. It is characterized by a high …

Simple Summary Cancers from the bile ducts and gall bladder are lethal. Cure by surgery is
not possible in most of these tumors as they are often identified in later stages. Unlike other …

Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The
majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack …

Vascular endothelial growth factors (VEGF), Vascular endothelial growth factor receptors
(VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic …

The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival
rate. Recent studies have indicated the involvement of epidermal growth factor receptor …

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue
sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the …